Allergan to buy MAP Pharma for about $958 mln
By Samuel Kwon
Jan 22, 2013 08:54 PM EST
Regions
U.S. specialty drugmaker Allergan Inc said late on Tuesday it will buy MAP Pharmaceuticals Inc for about $958 million in cash.
As per the deal, Allergan will acquire 100 percent of the shares of MAP Pharmaceuticals for a price of $25 per share, a 60 percent premium over MAP's closing stock price on the Nasdaq of $15.58 on Tuesday.
© 2024 VCPOST, All rights reserved. Do not reproduce without permission.
Join the Conversation